Fungal infections in burns: Diagnosis and management

ABSTRACT

Burn wound infection (BWI) is a major public health problem and the most devastating form of trauma worldwide. Fungi cause BWI as part of monomicrobial or polymicrobial infection, fungaemia, rare aggressive soft tissue infection and as opportunistic infections. The risk factors for acquiring fungal infection in burns include age of burns, total burn size, body surface area (BSA) (30–60%), full thickness burns, inhalational injury, prolonged hospital stay, late surgical excision, open dressing, artificial dermis, central venous catheters, antibiotics, steroid treatment, long-term artificial ventilation, fungal wound colonisation (FWC), hyperglycaemic episodes and other immunosuppressive disorders. Most of the fungal infections are missed owing to lack of clinical awareness and similar presentation as bacterial infection coupled with paucity of mycology laboratories. Expedient diagnosis and treatment of these mycoses can be life-saving as the mortality is otherwise very high. Emergence of resistance in non-albicans Candida spp., unusual yeasts and moulds in fungal BWI, leaves very few fungi susceptible to antifungal drugs, leaving many patients susceptible. There is a need to speciate fungi as far as the topical and systemic antifungal is concerned. Deep tissue biopsy and other relevant samples are processed by standard mycological procedures using direct microscopy, culture and histopathological examination. Patients with FWC should be treated by aggressive surgical debridement and, in the case of fungal wound infection (FWI), in addition to surgical debridement, an intravenous antifungal drug, most commonly amphotericin B or caspofungin, is prescribed followed by de-escalating with voriconazole or itraconazole, or fluconazole depending upon the species or antifungal susceptibility, if available. The propensity for fungal infection increases, the longer the wound is present. Therefore, the development of products to close the wound more rapidly, improvement in topical antifungal therapy with mould activity and implementation of appropriate systemic antifungal therapy guided by antifungal susceptibility may improve the outcome for severely injured burn victims.

KEY WORDS

Burns - fungal infections - moulds - yeasts

• REFERENCES

• 1 Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. Clin Microbiol Rev 2006;19:403-34.
• 2 Horvath EE, Murray CK, Vaghan GM, Chung KK, Hospenthal DR, Wade CE, et al. Fungal wound infection (not colonization) is independently associated with mortality in burn patients. Ann Surg 2007;245:978-85.
• 3 Mousa HA. Fungal infection of burn wound in patients with open and occlusive treatment methods. East Mediterr Health J 1999;5:333-6.
• 4 Tsoutsos D, Tsati E, Metaxotos N, Keramidas E, Rodopoulou S, Ioannovich J. Extensive burn injury complicated by mucormycosis: A case report. Ann Burns Fire Disasters 2001;16:1-2.
• 5 Gupta N, Hague A, Lattif AA, Narayan RP, Mukhopadhyay G, Prasad R. Epidemiology and molecular typing of Candida isolates from burn patients. Mycopathologia 2005;158:397-405.
• 6 Chakrabarti A, Chatterjee SS, Rao KL, Zameer MM, Shivaprakash MR, Singhi S, et al. Recent experience with fungemia: Change in species distribution and azole resistance. Scand J Infect Dis 2009;41:275-84.
• 7 Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion and E-test method: Report form the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol 2003;41:1440-6.
• 8 Chakrabarti A, Nayak N, Kumar PS, Talwar P, Panigarhi D, Chari PS. Surveillance of nosocomial fungal infections in a burn care unit. Infection 1992;20:132-5.
• 9 Murray C, Loo F, Hospenthal D, Cancio L, Jones J, Kim S, et al. Incidence of fungal infections and related mortality following severe burns. Burns 2008;34:1108-12.
• 10 Becker WK, Cioffi WG, McManus AT, Kim SH, McManus WF, Mason AD, et al. Fungal burn wound infection: A 10 year experience. Arch Surg 1991;126:44-8.
• 11 Ballard J, Edelman L, Saffle J, Sheridan R, Kagan R, Bracco D, et al. Multicentre Trials Group. American Burn Association. J Burn Care Res 2008;29:213-21.
• 12 Mousa HA. Aerobic anaerobic and fungal burn wound infections. J Hosp Infect 1997;37:317-23.
• 13 Schofield CM, Murray CK, Horvath EE, Cancio LC, Kim SH, Wolf SE, et al. Correlation of culture with histopathology in fungal burn wound colonization and infection. Burns 2007;33:341-6.
• 14 Cochran A. Systemic Candida infection in burn patients: A case-control study of management patterns and outcomes. Surg Infect (Larchmt) 2002;3:367-74.
• 15 Greenhalgh DG, Saffle JR, Holmes JH 4th, Gamelli RL, Palmieri TL, Horton JW, et al. American Burns Association Consensus Conference to define sepsis and infection in burns. J Burn Care Res 2007;28:776-90.
• 16 Mathew BP, Nath M. Recent approaches to antifungal therapy for invasive mycoses. ChemMedChem 2009;4:310-23.
• 17 Dries DJ. Management of burn injuries - recent developments in resuscitation, infection control and outcomes research. Scand J Trauma Resusc Emerg Med 2009;17:14.
• 18 Struck MF. Infection control in burn patients: Are fungal infections underestimated? Scand J Trauma Resusc Emerg Med 2009;17:51.
• 19 Macedo JL, Santos JB. Bacterial and fungal colonization of burn wounds. Braz J Infect Dis 2005;100:535-9.
• 20 Stone HH. Aspergillus infection of the burn wound. J Trauma 1979;19:765-7.
• 21 Burdge JJ, Rea F, Ayers L. Non-candidal fungal infections of burn wound. J Burn Care Rehabil 1988:9:599-1.
• 22 Paz RN, Strahilevitz J, Shapiro M, Keller N, Goldshmied-Reoven A, Yarden O, et al. Clinical and epidemiological aspect of infectious caused by Fusarium spp.: A collaborative study from Israel. J Clin Microbiol 2004;42:3456-61.
• 23 Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000;13:236-301.
• 24 Tang D, Wang W. Successful cure of an extensive burn injury complicated with mucor wound sepsis. Burns 1998;24:72-3.
• 25 Constantinides J, Misra A, Nassab R, Wilson Y. Absidia corymbifera fungal infection in burns: A case report and review of literature. J Burn Care Res 2008;29:416-9.
• 26 Caetano M, Ramos S, Abreu J, Casalta J, Pinheiro S, Diogo C, et al. Fungal infections at a Coimbra burns unit: 2003-2007 Abstract number: R2459. 18th European Congress of Clinical Microbiology and Infectious Diseases Barcelona, Spain, 19-22 April 2008.
• 27 Forbes BA, Sahm DF, Weissfeld L, Eissfeld AS. Bailey and Scott.s Diagnostic Microbiology. 11^th ed. Ohio: Mosby; 2002: 865-80.
• 28 Buchanan K. Comparison of quantitative and semiquantitative culture techniques for burn biopsy. J Clin Microbiol 1986;23:258.
• 29 Liu MZ. Need for more emphaisis on fungal infections in burn patients. Zhonghua Wai ke Za Zhi 1992;30:554-5, 573.
• 30 National Committee for Clinical Laboratory Standards 2002. Reference method for broth dilution testing of yeast approved standard. 2^nd ed, M27-A2. Wayne, Pa: National committee for clinical laboratory standards; 2002.
• 31 Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of Candidiasis: 2009 Update by the Infectious Disease Society of America. Clin Infect Dis 2009;48:503-35.
• 32 Patrice W. Mafenide tied to fungal infections in burn patients (Wound Healing). Skin Allergy News. Article date: 2008 Jul 1.
• 33 Yin HQ, Langford R, Burrell RE. Comparative evaluation of the antimicrobial activity of acticoat antimicrobial barrier dressing. J Burn Care Rehabil 1999;20:195-200.